texas oncology more breakthroughs. more victories

Share:

 
 

Expert on Benefit of Dual HER-2 Directed Therapy, MA17R Trial

Publication: Targeted Oncology

Dr. Frankie Holmes, a breast medical oncologist at Texas Oncology−Houston Memorial City, discusses the evolution of neoadjuvant HER2-directed therapy. Dr. Holmes also stresses the need for treatments for HER2-positive patients who do not meet the present criteria for the regimen.

Read the full story from Targeted Oncology.

Related Cancer Centers